ctDNA Pre-Radiation Predicts Oligometastatic NSCLC Survival

Measuring ctDNA levels before radiotherapy predicted PFS and overall survival, and can help determine the patients most likely to benefit from consolidation radiotherapy vs systemic therapy.
Medscape Medical News